Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, ArriVent BioPharma Inc’s stock clocked out at $23.47, up 3.30% from its previous closing price of $22.72. In other words, the price has increased by $3.30 from its previous closing price. On the day, 0.53 million shares were traded.
Ratios:
To gain a deeper understanding of AVBP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.34 and its Current Ratio is at 14.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on March 20, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On March 10, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $45. On July 22, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $35.Oppenheimer initiated its Outperform rating on July 22, 2024, with a $35 target price.
Stock Price History:
Over the past 52 weeks, AVBP has reached a high of $36.37, while it has fallen to a 52-week low of $15.47. The 50-Day Moving Average of the stock is 19.36%, while the 200-Day Moving Average is calculated to be -5.47%.
Shares Statistics:
A total of 34.04M shares are outstanding, with a floating share count of 19.42M. Insiders hold about 43.23% of the company’s shares, while institutions hold 59.52% stake in the company.
